共 37 条
Value of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the 'All-Comers' LEADERS Trial
被引:113
|作者:
Wykrzykowska, Joanna J.
[1
,13
]
Garg, Scot
[1
]
Onuma, Yoshinobu
[1
]
de Vries, Ton
[2
]
Goedhart, Dick
[2
]
Morel, Marie-Angele
[2
]
van Es, Gerrit-Anne
[2
]
Buszman, Pawel
[3
]
Linke, Axel
[4
]
Ischinger, Thomas
[5
]
Klauss, Volker
[6
]
Corti, Roberto
[7
]
Eberli, Franz
[7
]
Wijns, William
[8
]
Morice, Marie-Claude
[9
]
di Mario, Carlo
[10
]
van Geuns, Robert Jan
[1
]
Juni, Peter
[11
]
Windecker, Stephan
[12
]
Serruys, Patrick W.
[1
]
机构:
[1] Erasmus MC, Thoraxctr, Dept Intervent Cardiol, NL-3015 CE Rotterdam, Netherlands
[2] Cardialysis BV, Rotterdam, Netherlands
[3] Med Univ Silesia, Katowice, Poland
[4] Herzzentrum Leipzig, Leipzig, Germany
[5] Hosp Bogenhausen, Dept Cardiol, Munich, Germany
[6] Univ Hosp Munich Innenstadt, Dept Cardiol, Munich, Germany
[7] Univ Zurich Hosp, Dept Cardiol, CH-8091 Zurich, Switzerland
[8] Onze Lieve Vrouw Hosp, Dept Cardiol, Aalst, Belgium
[9] Inst Cardiovasc, Paris, Massy, France
[10] Royal Brompton Hosp, Dept Cardiol, London SW3 6LY, England
[11] CTU Bern, Bern, Switzerland
[12] Univ Hosp Bern, Dept Cardiol, CH-3010 Bern, Switzerland
[13] Univ Amsterdam, Acad Med Ctr, Dept Intervent Cardiol, NL-1105 AZ Amsterdam, Netherlands
关键词:
ACEF score;
SYNTAX score;
biolimus-eluting stent;
sirolimus-eluting stent;
biodegradable polymer;
cardiac death;
major adverse cardiac event;
ARTERY-DISEASE;
SYNTAX SCORE;
EUROSCORE;
STENT;
RECLASSIFICATION;
PREDICTOR;
MORTALITY;
D O I:
10.1161/CIRCINTERVENTIONS.110.958389
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Background-The age, creatinine, and ejection fraction (ACEF) score (age/left ventricular ejection fraction+1 if creatinine >2.0 mg/dL) has been established as an effective predictor of clinical outcomes in patients undergoing elective coronary artery bypass surgery; however, its utility in "all-comer" patients undergoing percutaneous coronary intervention is yet unexplored. Methods and Results-The ACEF score was calculated for 1208 of the 1707 patients enrolled in the LEADERS trial. Post hoc analysis was performed by stratifying clinical outcomes at the 1-year follow-up according to ACEF score tertiles: ACEF(low) <= 1.0225, 1.0225< ACEF(mid) <= 1.277, and ACEF(high) >1.277. At 1-year follow-up, there was a significantly lower number of patients with major adverse cardiac event-free survival in the highest tertile of the ACEF score ( ACEF(low) =92.1%, ACEF(mid) =89.5%, and ACEF(high) =86.1%; P=0.0218). Cardiac death was less frequent in ACEF(low) than in ACEF(mid) and ACEF(high) (0.7% vs 2.2% vs 4.5%; hazard ratio = 2.22, P=0.002) patients. Rates of myocardial infarction were significantly higher in patients with a high ACEF score (6.7% for ACEF(high) vs 5.2% for ACEF(mid) and 2.5% for ACEF(low); hazard ratio = 1.6, P = 0.006). Clinically driven target-vessel revascularization also tended to be higher in the ACEF(high) group, but the difference among the 3 groups did not reach statistical significance. The rate of composite definite, possible, and probable stent thrombosis was also higher in the ACEF(high) group ( ACEF(low) = 1.2%, ACEF(mid) =3.5%, and ACEF(high) =6.2%; hazard ratio=2.04, P<0.001). Conclusions-ACEF score may be a simple way to stratify risk of events in patients treated with percutaneous coronary intervention with respect to mortality and risk of myocardial infarction.
引用
收藏
页码:47 / 56
页数:10
相关论文